{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:05:18Z","timestamp":1758845118092,"version":"3.44.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA-040460"],"award-info":[{"award-number":["DA-040460"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.pbb.2023.173530","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T20:22:30Z","timestamp":1676665350000},"page":"173530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism"],"prefix":"10.1016","volume":"223","author":[{"given":"David B.","family":"Finlay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warwick","family":"Mackie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hunter D.J.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy R.","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mhairi","family":"Nimick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhonda J.","family":"Rosengren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie A.","family":"Marusich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Glass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny L.","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2023.173530_bb0005","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa1610300","article-title":"\u201cZombie\u201d outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York","volume":"376","author":"Adams","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pbb.2023.173530_bb0010","first-page":"137","article-title":"Synthetic cannabinoid induced acute respiratory depression: case series and literature review","volume":"22","author":"Alon","year":"2017","journal-title":"Respir. Med. Case. Rep."},{"key":"10.1016\/j.pbb.2023.173530_bb0015","first-page":"877","article-title":"Metabolic interactions with piperazine-based \u201cparty pill\u201d drugs","volume":"61","author":"Antia","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.pbb.2023.173530_bb0020","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1021\/acs.chemrestox.9b00466","article-title":"In vitro phase I metabolic profiling of the synthetic cannabinoids AM-694, 5F-NNEI, FUB-APINACA, MFUBINAC, and AMB-FUBINACA","volume":"33","author":"Apirakkan","year":"2020","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.pbb.2023.173530_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2020.110553","article-title":"In vitro characterization of new psychoactive substances at the \u03bc-opioid, CB1, 5HT 1A, and 5-HT 2A receptors-on-target receptor potency and efficacy, and off-target effects","volume":"317","author":"\u00c5strand","year":"2020","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.pbb.2023.173530_bb0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0014-2999(97)00021-6","article-title":"Comparison of relative potencies of i.V. And i.C.V. Administered 8-OH-DPAT gives evidence of different sites of action for hypothermia, lower lip retraction and tail flicks","volume":"323","author":"Bagdy","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2023.173530_bb0035","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1503\/cmaj.120951","article-title":"Grapefruit-medication interactions: forbidden fruit or avoidable consequences?","volume":"185","author":"Bailey","year":"2013","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.pbb.2023.173530_bb0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0149-7634(05)80051-X","article-title":"Delta 9-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication","volume":"16","author":"Balster","year":"1992","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pbb.2023.173530_bb0045","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/164_2018_143","article-title":"The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: origins","volume":"252","author":"Banister","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.pbb.2023.173530_bb0050","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acschemneuro.6b00137","article-title":"Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues","volume":"7","author":"Banister","year":"2016","journal-title":"ACS Chem. Neurosci."},{"issue":"30","key":"10.1016\/j.pbb.2023.173530_bb0055","first-page":"550","article-title":"N-Substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or \u2018Ecstasy\u2019)","volume":"303","author":"Baumann","year":"2004","journal-title":"Neuropsychopharmacol."},{"author":"Bennett","key":"10.1016\/j.pbb.2023.173530_bb0060"},{"key":"10.1016\/j.pbb.2023.173530_bb0065","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/bph.12329","article-title":"Real-time characterization of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action","volume":"170","author":"Cawston","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2023.173530_bb0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1523\/JNEUROSCI.0864-13.2014","article-title":"Dual effects of 5-HT(1a) receptor activation on breathing in neonatal mice","volume":"34","author":"Corcoran","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2023.173530_bb0075","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0014-2999(90)90319-2","article-title":"Comparison of the cardiovascular effects of the 5-HT1A receptor agonist flesinoxan with that of 8-OH-DPAT in the rat","volume":"180","author":"Dreteler","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2023.173530_bb0080","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1111\/bph.13866","article-title":"G\u03b1s signalling of the CB1 receptor and the influence of receptor number","volume":"174","author":"Finlay","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2023.173530_bb0085","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1021\/acschemneuro.9b00429","article-title":"Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity Profiles? A case study of AMB-FUBINACA","volume":"10","author":"Finlay","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pbb.2023.173530_bb0090","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1124\/jpet.117.246983","article-title":"Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-fluoro-CUMYL-PICA","volume":"365","author":"Gamage","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2023.173530_bb0095","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4103\/1658-354X.121062","article-title":"Methanol toxicity following esmolol infusion in a post-operative case of pheochromocytoma resection","volume":"7","author":"Ghatak","year":"2013","journal-title":"Saudi J Anaesth"},{"key":"10.1016\/j.pbb.2023.173530_bb0100","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1523\/JNEUROSCI.17-14-05327.1997","article-title":"Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a gs linkage to the CB1 receptor","volume":"17","author":"Glass","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2023.173530_bb0105","series-title":"Principles and Methods of Toxicology","first-page":"777","article-title":"Enzyme assay and purification","author":"Guengerich","year":"1989"},{"key":"10.1016\/j.pbb.2023.173530_bb0110","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1007\/s00213-014-3630-2","article-title":"Acute subjective effects after smoking joints containing up to 69 mg \u03949-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial","volume":"231","author":"Hunault","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2023.173530_bb0115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/bs.mie.2017.05.001","article-title":"Real-time measurement of cannabinoid receptor-mediated cAMP signaling","author":"Hunter","year":"2017","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.pbb.2023.173530_bb0120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/bs.pbr.2021.01.004","article-title":"Serotonin 2A receptors and cannabinoids","volume":"259","author":"Ibarra-Lecue","year":"2021","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.pbb.2023.173530_bb0125","doi-asserted-by":"crossref","first-page":"10576","DOI":"10.1074\/jbc.M609695200","article-title":"Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-Phosphate\/G 13 pathway","volume":"282","author":"Jiang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pbb.2023.173530_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2019.110107","article-title":"The phenomenon of Para-fluorophenylpiperazine (pFPP) in combination with the synthetic cannabinoid AMB-FUBINACA in seized plant material in New Zealand","volume":"307","author":"Johnson","year":"2020","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.pbb.2023.173530_bb0135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0028-3908(82)90157-5","article-title":"The effect of niaprazine on the turnover of 5-hydroxytryptamine in the rat brain","volume":"21","author":"Keane","year":"1982","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2023.173530_bb0140","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1124\/mol.104.006882","article-title":"Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?","volume":"67","author":"Kearn","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pbb.2023.173530_bb0145","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/03036758.2011.557036","article-title":"Benzylpiperazine in New Zealand: brief history and current implications","volume":"41","author":"Kerr","year":"2011","journal-title":"J. R. Soc. N. Z."},{"key":"10.1016\/j.pbb.2023.173530_bb0150","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11419-018-0430-0","article-title":"Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures","volume":"37","author":"Kevin","year":"2019","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.pbb.2023.173530_bb0155","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejphar.2013.02.009","article-title":"Effects of cholinesterase inhibitors and serotonin-1A receptor agonists on morphine-induced ventilatory depression and antinociception in rats","volume":"703","author":"Kimura","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2023.173530_bb0160","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0022-3565(24)36714-X","article-title":"Cannabinoid-induced hypotension and bradycardia in rats is mediated by CB1-like cannabinoid receptors","volume":"281","author":"Lake","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2023.173530_bb0165","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejphar.2007.09.022","article-title":"The cannabinoid CB1 receptor is expressed on serotonergic and dopaminergic neurons","volume":"578","author":"Lau","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2023.173530_bb0170","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0091-3057(01)00567-6","article-title":"Involvement of somatodendritic 5-HT(1A) receptors in Delta(9)-tetrahydrocannabinol-induced hypothermia in the rat","volume":"69","author":"Malone","year":"2001","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2023.173530_bb0175","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1080\/15563650.2021.1975734","article-title":"Respiratory failure in confirmed synthetic cannabinoid overdose","volume":"60","author":"Manini","year":"2022","journal-title":"Clin. Toxicol. (Phila)"},{"key":"10.1016\/j.pbb.2023.173530_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173467","article-title":"In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists","volume":"220","author":"Marusich","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2023.173530_bb0185","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1164\/ajrccm\/141.6.1527","article-title":"Effects of buspirone on sleep and respiration","volume":"141","author":"Mendelson","year":"1990","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.pbb.2023.173530_bb0190","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/dta.1541","article-title":"Characterizing metabolites and potential metabolic pathways for the novel psychoactive substance methoxetamine","volume":"6","author":"Menzies","year":"2014","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.pbb.2023.173530_bb0195","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/cne.901800302","article-title":"Serotonin neurons of the midbrain raphe: ascending projections","volume":"180","author":"Moore","year":"1978","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.pbb.2023.173530_bb0200","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1523\/JNEUROSCI.4147-13.2014","article-title":"Cocaine disrupts histamine H3 receptor modulation of dopamine D1 receptor signaling: \u03c31-D1-H3 receptor complexes as key targets for reducing cocaine\u2019s effects","volume":"34","author":"Moreno","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2023.173530_bb0205","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1523\/JNEUROSCI.0191-11.2011","article-title":"Dopamine-galanin receptor heteromers modulate cholinergic neurotransmission in the rat ventral hippocampus","volume":"31","author":"Moreno","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2023.173530_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100460","article-title":"An outbreak of deaths associated with AMB-FUBINACA in Auckland NZ","volume":"25","author":"Morrow","year":"2020","journal-title":"EClinicalMedicine"},{"year":"2011","series-title":"Guide for the Care and Use of Laboratory Animals","key":"10.1016\/j.pbb.2023.173530_bb0215"},{"key":"10.1016\/j.pbb.2023.173530_bb0220","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.neuropharm.2011.08.022","article-title":"On the role of brain 5-HT7 receptor in the mechanism of hypothermia: comparison with hypothermia mediated via 5-HT1A and 5-HT3 receptor","volume":"61","author":"Naumenko","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2023.173530_bb0225","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1100\/tsw.2008.136","article-title":"Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer","volume":"8","author":"Navarro","year":"2008","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.pbb.2023.173530_bb0230","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/3-540-26573-2_20","article-title":"Cardiovascular pharmacology of cannabinoids","volume":"168","author":"Pacher","year":"2005","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.pbb.2023.173530_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109865","article-title":"Biased agonism at the cannabinoid receptors \u2013 evidence from synthetic cannabinoid receptor agonists","volume":"78","author":"Patel","year":"2021","journal-title":"Cell. Signal."},{"key":"10.1016\/j.pbb.2023.173530_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113871","article-title":"Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists","volume":"175","author":"Patel","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pbb.2023.173530_bb0245","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/ALN.0000000000000490","article-title":"5-HT1A receptor agonist befiradol reduces fentanyl-induced respiratory depression, analgesia, and sedation in rats","volume":"122","author":"Ren","year":"2015","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pbb.2023.173530_bb0250","article-title":"Synthetic cannabis: adverse events reported to the New Zealand pharmacovigilance Centre","author":"Robson","year":"2020","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.pbb.2023.173530_bb0255","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.forsciint.2011.03.005","article-title":"New \u201cparty pill\u201d components in New Zealand: the synthesis and analysis of some \u03b2-ketone analogues of 3,4-methylenedioxymethamphetamine (MDMA) including \u03b2k-DMBDB (\u03b2-ketone-N, N-dimethyl-1-(1,3-benzodioxol-5-yl)-2-butanamine)","volume":"210","author":"Russell","year":"2011","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.pbb.2023.173530_bb0260","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0022-3565(24)35342-X","article-title":"Reversal of morphine-induced apnea in the anesthetized rat by drugs that activate 5-hydroxytryptamine(1A) receptors","volume":"292","author":"Sahibzada","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2023.173530_bb0265","first-page":"93","article-title":"Mass spectrometric studies of the metabolites of niaprazine","volume":"48","author":"Sanjuan","year":"1983","journal-title":"Int. J. Mass Spectrom."},{"key":"10.1016\/j.pbb.2023.173530_bb0270","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/0278-5846(88)90093-0","article-title":"Molecular pharmacology of niaprazine","volume":"12","author":"Scherman","year":"1988","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2023.173530_bb0275","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/09595230701255791","article-title":"Legal piperazine-containing party pills\u2013a new trend in substance misuse","volume":"26","author":"Sheridan","year":"2007","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.pbb.2023.173530_bb0280","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.forsciint.2019.04.014","article-title":"The identification and quantification of synthetic cannabinoids seized in New Zealand in 2017","volume":"300","author":"Somerville","year":"2019","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.pbb.2023.173530_bb0285","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40429-014-0014-y","article-title":"Synthetic cannabinoids: pharmacology, behavioral effects, and abuse potential","volume":"1","author":"Tai","year":"2014","journal-title":"Curr. Addict. Rep."},{"key":"10.1016\/j.pbb.2023.173530_bb0290","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s001340051208","article-title":"Effect of hypothermia on ventilation in anesthetized, spontaneously breathing rats: theoretical implications for mechanical ventilation","volume":"26","author":"Torbati","year":"2000","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.pbb.2023.173530_bb0295","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejphar.2009.05.010","article-title":"Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl\/6J mice","volume":"615","author":"Vann","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2023.173530_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002194","article-title":"Cognitive impairment induced by Delta9-tetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors","volume":"13","author":"Vi\u00f1als","year":"2015","journal-title":"PLoS Biol."},{"key":"10.1016\/j.pbb.2023.173530_bb0305","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11419-022-00649-3","article-title":"Characterisation of AMB-FUBINACA metabolism and CB1-mediated activity of its acid metabolite","volume":"41","author":"Webb","year":"2023","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.pbb.2023.173530_bb0310","article-title":"Brain penetrant, but not peripherally restricted, synthetic cannabinoid 1 receptor agonists promote morphine-mediated respiratory depression","author":"Wiese","year":"2021","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.pbb.2023.173530_bb0315","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuro.2019.04.002","article-title":"Do you feel it now? Route of administration and \u03949-tetrahydrocannabinol-like discriminative stimulus effects of synthetic cannabinoids in mice","volume":"73","author":"Wiley","year":"2019","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.pbb.2023.173530_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.08.025","article-title":"Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists","volume":"169","author":"Wouters","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pbb.2023.173530_bb0325","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/bph.12325","article-title":"Central 5-HT1A receptor-mediated modulation of heart rate dynamics and its adjustment by conditioned and unconditioned fear in mice","volume":"170","author":"Youn","year":"2013","journal-title":"Br. J. Pharmacol."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305723000175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305723000175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:45:13Z","timestamp":1758775513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305723000175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":65,"alternative-id":["S0091305723000175"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2023.173530","relation":{},"ISSN":["0091-3057"],"issn-type":[{"type":"print","value":"0091-3057"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2023.173530","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173530"}}